News

Sunshine Biopharma president and CEO Steve Slilaty said, "We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer

The project was based on using ERC technology licensed from Yale University to treat type 1diabetes. Shumakov Center Biomedical Research and Technology Institute head and professor Viktor Sevastianov

Eclipse develops drug candidates, such as ET101 that targets cancer stem cells (CSCs), which are the seeds at the root of cancer. Bionomics CEO and managing director Deborah

Under the agreement, Oxford Pharmascience will develop and commercialize various re-formulated statins, using the generic cholesterol-lowering drugs, atorvastatin and simvastatin. In addition, Oxford has established the feasibility of

The migraine treatment drug candidate, MSRX-202, leverages MonoSol PharmFilm technology in a combination product that includes rizatriptan for the treatment of migraine pain and ondansetron for the treatment

DARA plans to launch Gelclair, a topical gel used to coat and protect the oral cavity to reduce pain, in the first quarter of 2013. DARA chief executive

Reverse-vine is an extract which contains stilbenes, natural compounds produced by the grapevine as part of their defense system including resveratrol, reports naturalproductsinside. In addition, the product includes

Patients with metastatic stage IIIB, or stage IV, or recurrent squamous cell carcinoma of the lung who are chemotherapy naïve for their metastatic or recurrent cancer were treated

Cenergy Nutrition Line of Products will be exhibited between 27-30 September, according to the company. Bill Chaaban CEO said the Cenergy line is a big part of the